NOVEL GROUPS OF BIOMARKERS FOR DIAGNOSING ALZHEIMER'S DISEASE
First Claim
Patent Images
1. A method of aiding diagnosis of Alzheimer'"'"'s disease (“
- AD”
), comprising;
a) measuring a level of each of at least three AD diagnosis biomarkers in a biological fluid sample in an individual, wherein the at least three AD diagnosis biomarkers are selected from the group consisting of;
ACE (angiotensin converting enzyme or CD143), alpha-1-antitrypsin, Apo AI (apolipoprotein AI), Apo CIII (apolipoprotein CIII), Apo E (apolipoprotein E), CRP (C-reactive protein), cortisol, FGF-4 (fibroblast growth factor-4), MCP-3 (monocyte chemotactic protein-3), MMP-9 (matrix metalloproteinase-9), and TRAIL R3 (Receptor-3 for Tumor necrosis factor-related apoptosis-inducing ligand)b) implementing a scoring algorithm;
c) generating a score based on the measured levels of the AD diagnosis biomarkers; and
d) comparing the score with a cutoff score, wherein the diagnosis of AD is aided by determining whether the score is above, equal to, or below the cutoff score;
wherein the method has an accuracy of at least about 65% in classifying the individual as either having Alzheimer'"'"'s disease or nondemented.
1 Assignment
0 Petitions
Accused Products
Abstract
The inventors have discovered sets of proteinaceous biomarkers which can be measured in biological fluid samples to diagnosis or aid in the diagnosis of Alzheimer'"'"'s disease and distinguish AD samples from non-demented samples.
-
Citations
27 Claims
-
1. A method of aiding diagnosis of Alzheimer'"'"'s disease (“
- AD”
), comprising;a) measuring a level of each of at least three AD diagnosis biomarkers in a biological fluid sample in an individual, wherein the at least three AD diagnosis biomarkers are selected from the group consisting of;
ACE (angiotensin converting enzyme or CD143), alpha-1-antitrypsin, Apo AI (apolipoprotein AI), Apo CIII (apolipoprotein CIII), Apo E (apolipoprotein E), CRP (C-reactive protein), cortisol, FGF-4 (fibroblast growth factor-4), MCP-3 (monocyte chemotactic protein-3), MMP-9 (matrix metalloproteinase-9), and TRAIL R3 (Receptor-3 for Tumor necrosis factor-related apoptosis-inducing ligand)b) implementing a scoring algorithm; c) generating a score based on the measured levels of the AD diagnosis biomarkers; and d) comparing the score with a cutoff score, wherein the diagnosis of AD is aided by determining whether the score is above, equal to, or below the cutoff score; wherein the method has an accuracy of at least about 65% in classifying the individual as either having Alzheimer'"'"'s disease or nondemented. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
- AD”
-
2. A computer implemented method of diagnosing or aiding diagnosis of Alzheimer'"'"'s disease (“
- AD”
) comprising;
a) implementing a scoring algorithm;
b) generating a score based on measured levels of a set of AD diagnosis biomarkers in a biological fluid sample in an individual; and
c) comparing the score with a cutoff score, wherein the diagnosis of AD is made or aided by determining whether the score is above, equal to, or below the cutoff score, wherein the set of AD diagnosis biomarkers comprises at least three AD diagnosis biomarkers, wherein the at least three AD diagnosis biomarkers are selected from the group consisting of;
ACE (angiotensin converting enzyme or CD
143), alpha-1-antitrypsin, Apo AI (apolipoprotein AI), Apo CIII (apolipoprotein CIII), Apo E (apolipoprotein E), CRP (C-reactive protein), cortisol, FGF-4 (fibroblast growth factor-4), MCP-3 (monocyte chemotactic protein-3), MMP-9 (matrix metalloproteinase-9), and TRAIL R3 (Receptor-3 for Tumor necrosis factor-related apoptosis-inducing ligand), and wherein the method has an accuracy of at least about 65% in classifying the individual as either having Alzheimer'"'"'s disease or nondemented.
- AD”
Specification